In search of potential androgen receptor coregulators we performed a yeast two-hybrid screening using the androgen receptor ligand-binding domain as bait and a human prostate cDNA library as prey and found that the carboxy-terminal domain of retinoblastoma-associated Krüppel protein (RbaK), a member of the Krüppel zinc finger protein family, interacts in a ligand-dependent way with the ligand-binding domain of the androgen receptor. RBaK was recently identified as a transcriptional regulator that interacts with the retinoblastoma protein and thereby influences E2F regulated transcription. The interaction of RBaK with the androgen receptor was further documented using mammalian two-hybrid experiments, in vitro binding studies and coimmunoprecipitation. Finally, we demonstrated that both RBaK and the retinoblastoma protein coactivate androgen receptor-mediated transcription in cotransfection experiments. In conclusion, our data show that RBaK interacts with the androgen receptor and increases its transcriptional activity. Moreover, the double interaction of RBaK with the retinoblastoma protein and with the androgen receptor provides a novel link between the androgen receptor and the regulation of the cell cycle.
Introduction
The androgen receptor (AR) is a member of the large family of nuclear receptors (NRs) that activate (or repress) gene expression upon ligand binding (Evans 1988 , Parker 1993 , Tsai & O'Malley 1994 , Mangelsdorf & Evans 1995 and plays an essential role in the differentiation, development and normal function of male sex organs. After androgen binding the activated receptor interacts with androgen-responsive elements present in the regulatory regions of androgen-responsive genes and thereby changes their transcriptional rate. In addition to such direct genomic effects, androgens also exert more indirect effects through the regulation of other intracellular pathways (Swinnen et al. 1997) or through changes in the secretion or activity of several growth factors or growth factor receptors (Schuurmans et al. 1991 , Yan et al. 1992 , Zuck et al. 1992 , Hall et al. 1993 , Horton et al. 1993 , Fasciana et al. 1996 , Kim et al. 1996 . Moreover, the AR may be activated independently from androgen action, e.g. by protein kinases, which in turn may be regulated by growth factors (Nazareth & Weigel 1996 , Darne et al. 1998 , Wen et al. 2000 .
During the last few years there has been growing evidence that the activity of steroid hormone receptors is modulated further through interaction with intracellular coregulator proteins, which increase or repress the hormone response by various mechanisms such as histone acetylation (Pazin & Kadonaga 1997) or chromatin remodeling (Pollard & Peterson 1998) . Most of these coregulators interact with several steroid hormone receptors, but receptor specificity has been claimed for some of them. A common approach for the detection of novel coregulators consists of an initial screening of a suitable cDNA library for proteins interacting with an NR by means of the yeast two-hybrid system, followed by confirmation of the interaction by various techniques and demonstration of coregulatory properties by means of cotransfection.
In this report we identified one of the proteins interacting with the ligand-binding domain (LBD) of the AR in the yeast two-hybrid system as RBaK. RBaK (for retinoblastoma-associated Krüppel protein) was recently described (Skapek et al. 2000) based on its interaction with retinoblastoma (Rb), a protein that not only plays a crucial role in the regulation of cell proliferation (Weintraub et al. 1995 , La Thangue 1996 , Dyson 1998 , Harbour & Dean 2000 but also has coactivator properties for the AR (Lu & Danielsen 1998 , Yeh et al. 1998 and for other NRs (Singh et al. 1995) . RBaK is a member of a large family of transcriptional regulators that contain multiple Krüppel type zinc fingers linked to a KRAB (Krüppel-associated box) repressor motif at its amino-terminal side. As shown by Skapek et al. (2000) , RBaK interacts with Rb through the linker sequence between the KRAB domain and the zinc finger region and affects the important control function of Rb in the cell cycle, through regulation of the activity of E2F transcription factors (Weintraub et al. 1995 , La Thangue 1996 , Dyson 1998 , Harbour & Dean 2000 .
In this communication we show that the carboxy-terminal part of RBaK mediates the interaction of RBaK with the AR. This interaction was confirmed by binding studies and by coimmunoprecipitation experiments. Finally, we demonstrate that RBaK coactivates AR-mediated transcription in COS-7 cells and in CV-1 cells, even when the transcriptional activity of the AR in CV-1 cells is already increased by cotransfection with Rb. For that reason RBaK may be considered as a novel AR coactivator. Moreover, it is conceivable that the double interaction of RBaK with the AR and with Rb plays a role in the regulation of cell proliferation by androgens, a process wherein the control of E2F activity by Rb is an important step.
Materials and methods

Yeast strain and plasmids
The yeast strain Y190 (Saccharomyces cerevisiae) was obtained from Clontech Laboratories as a component of the MATCHMAKER two-hybrid system. The yeast shuttle vectors pAS2-1 (which expresses the DNA-binding domain (DBD) of Gal4 (Gal4 DBD)) and pACT2 (expressing the activation domain (AD) of Gal4 (Gal4AD)) were also obtained from Clontech. The yeast vector pGBT9 (Gal4 DBD) was a gift of Dr Michael R Stallcup (University of Southern California, Los Angeles, CA, USA). Dr Stallcup also provided pGBT9 constructs containing the LBD of the following receptors in frame with the Gal4 DBD: human AR (AR 644-919 ), mouse glucocorticoid receptor ), human estrogen receptor (ER 274-595 ), human retinoic acid receptor ), human thyroid hormone receptor ), human vitamin D receptor ) and human retinoid X receptor ). Dr Hinrich Gronemeyer (IGBMC, Strasbourg, France) provided the expression vectors for TIF2 (pSG5-TIF2 and pSG5-TIF2·5). pSG5-VDR was a gift of Dr Carsten Carlberg (Heinrich-Heine Universitaet, Dusseldorf, Germany). Dr Tony Kouzarides (University of Cambridge, UK) kindly provided pcDNA3-Rb. Finally, pMOR (expressing the mouse ER ) and p(Gal4) 5 -TK-luciferase were provided by Dr Malcolm G Parker (Imperial College, Faculty of Medicine, London, UK). The modified pSNATCHII expression vector (expressing the VP16 AD) was described in Alen et al. (1999a) .
DNA manipulations
Plasmids were constructed and isolated according to standard methods. The Gal4 DBD-AR(LBD) fusion construct was generated by amplification of the hinge region and LBD (amino acids (aa) 624-919) of the human AR with the forward primer 5 -gcgacgCATATGACTCTGGGAGCCC GGAAGCTGAAGAAACTT-3 and the reverse primer 5 -atctatGGATCCTTCACTGGGTGTG GAAATATAGGGGCTTGAC-3 . The underlined sequences are NdeI and BamHI restriction sites respectively. The amplified NdeI-BamHI digested product was then cloned in frame in the homologous sites of the pAS2-1 vector (Clontech) yielding the plasmid pAS2-AR(LBD). The TIF2·5 (aa 624-869) fragment (Voegel et al. 1998 ) was amplified using 5 -atatatGGATCCGAGAGAGCT GACGGGCAGAGCAG-3 as forward primer, 5 -atatatGGATCCCTAGCTCTGTGAAATTCG CAGTCG-3 as reverse primer and the pSG5-TIF2·5 plasmid as template. The amplified and BamHI digested product was then ligated into the BamHI site of pACT2 (Clontech) . The complete open reading frame (ORF) of RBaK was obtained as follows: RNA was prepared from normal human prostate tissue as described by Swinnen et al. (1994) . cDNA was synthesized using the RT-PCR kit from Life Technologies according to the manufacturer's protocol. The complete ORF of RBaK was amplified using 5 -aaatGGATCCATGAACACA TTGCAGGGGCC-3 as forward primer and 5 -aaatGGATCCTCAGAGATTTTCCACATCA AG-3 as reverse primer. The amplified product was subcloned in pGEM-T (Promega) and sequenced. After insert excision from pGEM-T with BamHI, the RBaK ORF was cloned in the sense (S) and anti-sense (AS) direction into a pSG5-HA vector which expresses the viral hemagglutinin (HA) epitope, yielding pSG5-HARBaK(S) and pSG5-HA-RBaK(AS) respectively. The pSG5-HA vector itself was prepared by cloning a double stranded oligonucleotide (5 -CCACCATG*TACCCATACGATGTTCCAGAT TACGCT-3 with the Kozak sequence in italics and ATG* as start codon) encoding the HA epitope with sticky EcoRI ends in the homologous EcoRI site of the pSG5 vector. The pRSET-A-RBaK carboxy-terminal domain (CTD: RBaK ) and the pSNATCHII-RBaKCTD sense and anti-sense constructs were generated from the pACT2-RBaKCTD plasmid picked up in the yeast two-hybrid screening by insert excision with BglII. The insert, which also contains the HA epitope sequence from the pACT2 vector 5 in frame with the RBaKCTD sequence, was then cloned in the corresponding BamHI sites of the pRSET-A (Invitrogen) and of the pSNATCHII vector. To generate the pSG5-Rb construct, the Rb ORF was amplified from the pcDNA3-Rb construct using 5 -aaatggatCCACCATGCCGCCCAAAACCCCC CG-3 as forward primer and 5 -aaatggatcc TCATTTCTCTTCCTTGTTTGAGG-3 as reverse primer. The amplified, BamHI digested product was cloned in the corresponding BamHI site of pSG5. The pSG5-3 FLAG-AR expression construct, the AR deletion constructs and the AR point mutations were constructed as described previously (Alen et al. 1999b) .
Yeast manipulations
Standard microbiological techniques and media were used according to the manufacturer's protocol. Yeast was transformed via the lithium acetate procedure as in the protocol of Gietz et al. (1995) . For the cycloheximide resistance selection, yeast was plated out on medium containing 10 µg/ml cycloheximide. Transformants were allowed to grow at 30 C until the colonies were sufficiently large to assay for -galactosidase activity. In short, transformed cells were filter plated on a sterile Whatman Number 5 filter. Cells were then permeabilized by a cycle of freezing in liquid nitrogen and thawing at room temperature. Each filter was then soaked into an appropriate amount of Z-buffer containing 5-bromo-4-chloro-3-indolyl---galactopyranoside and incubated at 30 C until blue colonies appeared (between 0·5 and 8 h).
For quantitative studies of NR transactivation activity, a liquid -galactosidase assay was used. His + /LacZ + yeast transformants were grown to stationary phase in the single dropout (SD) medium SD/ Trp/ His/ Leu containing 40 mM 3-amino-1,2,4-triazole (3-AT) and the appropriate concentration of ligand. The saturated culture was diluted in YPD medium to an A 600 of 0·2 and the yeast was grown to midlog phase (A 600 0·6; approximately 3 h). Then 1·5 ml of the culture were centrifuged, the pellet was washed once with 1·5 ml Z-buffer and resuspended in 300 µl Z-buffer. One hundred and fifty microliters of cell suspension were then permeabilized by two cycles of freezing in liquid nitrogen and thawing at 37 C. Finally, 50 µl were used for chemiluminescent detection of -galactosidase using Clontech's luminescent -galactosidase genetic reporter system II. To test the ligand-dependency of the interaction, His + /LacZ + yeast transformants were grown in SD/ Trp/ Leu medium supplemented with or without ligand. Subsequently, the liquid -galactosidase assay was performed. The following ligands were used: 10 nM methyltrienolone (R1881, a synthetic androgen) for the AR, 0·1 µM estradiol for the ER, 50 µM dexamethasone for the GR, 1 µM 1,25-dihydroxyvitamin D 3 for the VDR, 1 µM all-trans retinoic acid for the RAR, 10 µM 9-cis retinoic acid for the RXR and 10 µM triiodothyronine for the TR. All hormone stock solutions were prepared in ethanol, except triiodothyronine, which was dissolved in water. The final concentration of ethanol never exceeded 0·1%. Where appropriate the same concentration of ethanol was added to the control incubations.
Two-hybrid screening pAS2-ARLBD was transformed into Y190 using the lithium acetate method. The transformed colonies were grown overnight in SD/ Trp to ensure that they contained the bait plasmid. Thereafter, the culture was transformed with the human prostate cDNA MATCHMAKER library (obtained from Clontech) and double transformants were plated out on SD/ Trp/ Leu/ His plates containing 40 mM 3-AT and 10 nM R1881. Then the plates were incubated at 30 C until colonies appeared. His + clones were picked up, restreaked at least once on triple minus plates and then assayed for the LacZ phenotype.
Library plasmids from His + , LacZ + clones were rescued via cycloheximide selection and retransformed alone, with pAS2-ARLBD or with a Gal4 DBD-laminin control expression plasmid. Library plasmids that activated LacZ only in the presence of the bait plasmid were then sequenced using autoread-sequencing kits and an ALF automated laser fluorescence sequencer (Amersham-Pharmacia).
In vitro binding experiments
To study the interactions of various 35 S-labeled NRs with the fragment of RBaK isolated during the screening (RBaKCTD: RBaK 417-714 ), RBaKCTD was prepared as a (His) 6 -fusion protein and immobilized on Talon matrix (Clontech). Therefore the pRSET-A-RBaKCTD plasmid was transformed in BL21(DE3)pLysS Escherichia coli cells (Stratagene). (His) 6 -fusion proteins were expressed and purified under denaturing conditions on the TALON-matrix according to the manufacturer's protocol. For the expression of the AR, GR, ER, VDR, Rb or luciferase labeled with [
35 S]methionine (.1000 Ci/mmol, Amersham) the corresponding pSG5 expression constructs were used as templates in the TNT-coupled T7 transcription translation reticulocyte lysate system (Promega). The synthesis of these receptors was performed in both the presence (10 nM) or absence of their respective ligand (R1881 for the AR, estradiol for the ER, dexamethasone for the GR and 1,25-dihydroxyvitamin D 3 for the VDR).
To study the interaction, 22·5 µl 35 S-labeled lysate were incubated with 50 µl TALON to which the purified (His) 6 -fusion protein had been bound or with 50 µl TALON alone. NETN-buffer (0·02% NP40, 20 mM Tris-HCl pH 8·0, 100 mM NaCl and 1 mM EDTA) was added to a final volume of 250 µl. After incubation for 3 h at 4 C on a slowly rotating wheel, the matrix was washed four times with 1 ml NETN buffer. Bound proteins were eluted by adding 50 µl SDS loading buffer and boiling. Finally, the eluted proteins were separated by SDS-PAGE and visualized by autoradiography.
Transfections of mammalian cells
CV-1 cells or COS-7 cells (seeded at a density of 15 000 cells/well of a 48-well plate) were cultured in Dulbecco's modified Eagle's medium (Life Technologies) containing 10% fetal calf serum. Cotransfection experiments were performed using the Fugene-6 method (Roche) as previously described (Hofman et al. 2000) with (per well) 100 ng reporter construct (C3 ARE-luciferase), 0·17 ng pSG5-AR and various amounts of pSG5 expression constructs as indicated in the figures. For the mammalian two-hybrid experiments, cells were transfected with (per well) 100 ng p(Gal4) 5 -TK-luciferase reporter construct, 0·67 ng pAB-Gal4 DBD-ARLBD construct and 0·67 ng pSNATCHII, pSNATCHIIRBaK(S) or pSNATCHII-RBaK(AS) construct respectively.
Preparation of nuclear extracts
For the preparation of nuclear extracts, COS-7 cells were seeded out at a density of 3 10 6 cells in a 14 cm plate. After 24 h of culture the cells were transfected with (per plate) 4 µg pSG5-3 FLAG-AR and 4 µg pSG5-HA-RBaK. In the control conditions 4 µg pSG5-AR and 4 µg pSG5-HA-RBaK or 4 µg pSG5-HA-RBaK and 4 µg pGEM7zf+ were transfected. pGEM7zf+ was used to keep the amount of transfected DNA constant. Sixteen hours after transfection cells were treated for 24 h with 10 nM R1881, a strong AR agonist. Then, the cells were washed twice with 3 ml ice-cold PBS, collected in 1·5 ml ice-cold PBS, transferred to a prechilled microcentrifuge tube and centrifuged down briefly. After removal of the supernatant the pellet was resuspended in 400 µl freshly made cold hypotonic buffer. This buffer consisted of 4 volumes 10 mM Hepes-KOH buffer (pH 7·9), 10 mM KCl and 1·5 mM MgCl 2 and 1 volume of a solution containing one Minitablet of Complete Protease Inhibitors (Roche) dissolved in 1·5 ml water. The resuspended pellet was incubated on ice for 10 min, vortexed for 30 s and centrifuged for 10 s. The supernatant was removed and the nuclear pellet was incubated in 100 µl ice-cold high-salt buffer. This buffer consisted of 3 volumes 20 mM Hepes-KOH buffer pH 7·9, 420 mM KCl, 25% glycerol, 1·5 mM MgCl 2 and 1 volume of the protease inhibitor solution. This mixture was further incubated on ice for 20 min and then vortexed for 10 s. Debris were centrifuged down for 2 min at 4 C at 14 000 g and the supernatant was transferred to a prechilled microcentrifuge tube. Finally, the protein concentration of the nuclear extract was measured using bicinchoninic acid after trichloroacetic acid precipitation (Brown et al. 1989) . Nuclear extracts were stored at 70 C.
Immunoprecipitation
For the immunoprecipitation of FLAG-tagged AR, the EZview Red ANTI-FLAG M2 affinity gel (Sigma) was used. Five microliters of the 50% bead slurry were used for 50 µg nuclear extract protein (see above). This bead slurry was washed twice with 100 µl TBS (50 mM Tris-HCl, pH 7·4 and 150 mM NaCl) and centrifuged down for 10 s at 4 C. After addition of 50 µg nuclear extract protein in 100 µl lysis buffer (50 mM Tris-HCl pH 7·4, 150 mM NaCl, 1 mM EDTA and 1% Triton X-100) the mixture was incubated for 2 h at 4 C on a slowly rotating wheel. Then, the mixture was centrifuged down for 10 s at 4 C and the supernatant was removed. Thereafter, the beads were washed twice with 500 µl TBS by incubation on a rotating wheel for 15 min at 4 C. Finally, the beads were boiled for 5 min in 20 µl 1 sample buffer and the eluted proteins were size fractionated onto an SDS-PAGE gel and visualized by immunoblotting. For the detection of HA-tagged RBaK we used a monoclonal antibody directed against the viral HA epitope and directly labeled with horseradish peroxidase (HRP) from Roche. A rabbit polyclonal antibody raised against an amino-terminal peptide (aa 1-20) was used for the detection of the AR (Aumüller et al. 1998) in combination with goat-anti-rabbit immunoglobins/ HRP from Dako as secondary antibody.
Results
Characterization of RBaK as an AR-interacting protein by yeast two-hybrid screening
To screen for proteins interacting with the LBD of the AR (ARLBD), the yeast strain Y190, previously transformed with pAS2-ARLBD (expressing the Gal4 DBD-ARLBD fusion protein), was transformed with a human prostate-derived cDNA library expressed as fusion proteins with the Gal4AD. Approximately 4 10 6 yeast transformants were screened in the presence of 10 nM R1881, a strong AR agonist. One of the clones showing strong ligand-dependent interaction with the ARLBD encodes a 297 amino acid long peptide. The complete ORF of this clone was sequenced and the corresponding peptide was found to be 100% identical to the carboxy-terminal part of RBaK, a recently identified protein that interacts with Rb (Skapek et al. 2000) .
RBaK-NR LBD interaction in yeast
In yeast, the fragment of RBaK isolated in the yeast two-hybrid screening (Gal4AD-RBaK AA417-741) interacted with the Gal4 DBD-ARLBD in a ligand-dependent way, suggesting that R1881 induced a conformational change of the AR required for protein-protein interaction. Indeed, growth of yeast transformed with pAS2-ARLBD and pACT2-RBaKCTD in SD/ Trp/ Leu/ His medium was only observed in the presence of the ligand. Moreover, when the positive clone was grown in SD/ Trp/ Leu medium there was little or no -galactosidase activity (measured in the liquid assay) in the absence of ligand, but the activity increased markedly as a function of the concentration of R1881 (Fig. 1A) with a maximal 60-fold stimulation at 10 nM. Near maximal stimulation was reached at 3 nM. For yeast transformed with pAS2-ARLBD alone no -galactosidase activity was observed in the presence or in the absence of R1881.
In order to evaluate receptor specificity, the Gal4AD-RBaKCTD construct was cotransformed in yeast with Gal4 DBD-LBD constructs of the AR, GR, ER, VDR, RXR, RAR and TR. As positive controls we looked at the interaction between the Gal4 DBD-LBD of these NRs and Gal4AD-TIF2·5. Whereas the Gal4AD-TIF2·5 construct produced no galactosidase activity in itself, significant ligand-dependent interactions with TIF2·5 were observed for all NRs (Fig. 1B) . For the RBaKCTD, however, only the LBD of the AR displayed a strong ligand-dependent interaction (Fig. 1B) , which was even stronger than that observed for TIF2·5. It should be noted that LacZ + yeast colonies did arise when the Gal4 DBD-GR(LBD) or the Gal4 DBD-ER(LBD) construct were cotransformed with the Gal4AD-RBaKCTD construct in the presence of ligand, but these interactions were very weak in the liquid -galactosidase test (Fig. 1B) .
In vitro interaction of RBaK with the AR
To confirm the RBaK-AR interaction in vitro, 35 S-labeled full-length AR was added to (His) 6 -RBaKCTD coupled to TALON matrix or to the TALON matrix alone. As shown in Fig. 2 , a clear interaction of the AR with the RBaKCTD was observed in vitro. This in vitro interaction was ligand-independent -in contrast to the interaction in yeast -and not antagonized by the antiandrogen hydroxyflutamide (data not shown).
Using similar procedures we also tested the in vitro interaction between RBaKCTD and the GR, ER, VDR or Rb. The interaction of RBaKCTD with luciferase was used as a negative control. Under these conditions the strongest interaction was observed with the AR but there also was clear interaction with the GR and to a lesser extent with the ER (Fig. 2) . Only weak interaction was seen with the VDR or Rb. The lack of interaction with Rb is not unexpected, since it is not the RBaKCTD but the linker region between the amino-terminal KRAB domain and the zinc finger domain of RBaK that is required for the interaction with Rb (Skapek et al. 2000) . In our hands this region of RBaK, however, did not interact with the AR either in vitro or in yeast (data not shown).
To further characterize the region of the AR required for the interaction with RBaK, AR deletion mapping experiments were performed using carboxy-terminally truncated receptors, since RBaK was isolated in a screening with the ARLBD. Based on the alignment of Würtz et al. (1996) , we generated the following deletion mutants: AR-1 (AR 1-723 ) ending after H3 (aa 698-720), AR-2 (AR 1-697 ), AR-3 (AR 1-684 ) ending after H1 (aa 677-684), AR-4 (AR 1-671 ) ending after the hinge region (aa 627-670) and AR-5 (AR 1-627 ) ending after the DBD (aa 539-627). As shown in Fig. 3 , the binding was well conserved for the AR-1 mutant, which no longer binds androgens, but most of the binding was lost when H3 was deleted (AR-2). This observation suggests that the H3-containing domain strongly contributes to the interaction between the AR-LBD and RBaK-CTD. Remarkably, point mutations of residues located in H3 and previously reported to 
Coimmunoprecipitation of RBaK with the AR
To demonstrate that RBaK interacts in vivo with the AR, coimmunoprecipitation experiments were performed using FLAG-tagged AR and an antibody against the FLAG sequence for immunoprecipitation. Nuclear extracts were prepared from COS-7 cells cotransfected with pSG5-3 FLAG-AR together with pSG5-HA-RBaK(S) and grown in the presence or absence of 10 nM R1881. In the control conditions, COS-7 cells were transfected both with pSG5-AR and pSG5-HA-RBaK(S) or with pSG5-HA-RBaK(S) alone. As shown in Fig. 4A , RBaK was nearly undetectable in the immunoprecipitate when coimmunoprecipitation experiments were performed with non-flagged AR or in the absence of AR. However, there was marked coimmunoprecipitation of HA-RBaK with the AR when the cells were cotransfected with flagged AR and HA-RBaK, indicating that the RBaK protein was associated with the AR. The degree of coimmunoprecipitation of RBaK, however, was not influenced by the presence of androgen (Fig. 4B) .
Mammalian two-hybrid interaction
The interaction between the AR and RBaK was also analyzed by means of a mammalian twohybrid experiment, using a Gal4 DBD-ARLBD fusion construct and VP16AD-RBaK fusion constructs wherein RBaK was cloned in the sense or in the anti-sense orientation or VP16AD alone as a control. After cotransfection of COS-7 cells with these expression constructs, the addition of ligand increased the Gal4 driven luciferase response for the RBaK(S) construct (Fig. 5) , but not for the other constructs. Consequently, the AR-LBD interacts with RBaK in a ligand-dependent way in a mammalian as well as in a yeast two-hybrid system, in contrast to the results of the in vitro binding and coimmunoprecipitation experiments, wherein the interaction of the AR with RBaK was ligand-independent.
Influence of RBaK on AR-mediated transcription
To evaluate the potential of RBaK as an AR coregulator, cotransfection experiments were performed in CV-1 cells and COS-7 cells. In these experiments the effect of a sense RBaK expression construct (RBaK(S)) was compared with an antisense RBaK expression construct (RBaK(AS)) or to the pSG5 1 control. This construct contains an unrelated cDNA fragment (NuRIP-6) without coregulator properties but which has approximately the same size as the RBaK insert and therefore produces nearly the same suppression of the concentration of the AR (Hofman et al. 2000) . As shown in Fig. 6 , very similar concentrations of the AR in the presence of ligand were obtained for the three constructs. In COS-7 cells, however, the expression of the AR was stronger than in CV-1 cells and therefore required a shorter exposure time. In both cell lines the cotransfection with RBaK(S) markedly increased the ligand-induced activity of the C3 ARE-Luc-reporter construct, as compared with cotransfection with RBaK(AS) or with the inactive 1 control construct. For that reason, the cotransfection data support a role of RBaK as an AR coactivator.
Influence of Rb on RBaK-mediated AR coactivation
Since the amino-terminal half of RBaK interacts with Rb (Skapek et al. 2000) , which in turn may interact with the NTD of the AR and coactivate its function (Singh et al. 1995 , Lu & Danielsen 1998 , Yeh et al. 1998 , there could be a link between these interactions with formation of a ternary complex. However, the similar degree of AR coactivation in COS-7 cells and in CV-1 cells suggests that the coactivation by RBaK is not mediated by Rb. Nuclear extracts were incubated with an ANTI-FLAG M2 affinity gel. Bound proteins were eluted by boiling the gel in 1×sample buffer. Proteins were separated by SDS-PAGE and electroblotted onto a nitrocellulose membrane, which was probed with a polyclonal antiserum against the AR or with a monoclonal antiserum against the HA-epitope (see Materials and methods). Immunoreactive proteins were visualized by chemiluminescence. Input lanes are equivalent to 50% of the amount applied for the AR and 4% of the amount applied for RBaK. (B) Influence of ligand on the coimmunoprecipitation of RBaK. COS-7 cells were cotransfected with pSG5-3FLAG-AR and with pSG5-HA-RBaK and incubated without ligand or with 10 nM R1881. A monoclonal antiserum against the HA epitope was used for immunodetection. Indeed, in COS-7 cells, but not in CV-1 cells, the function of Rb is strongly suppressed by expression of the large T antigen (Ludlow et al. 1989 ) and this applies also to the coactivation of the AR by Rb (Lu & Danielsen 1998) . In line with their results, we observed that cotransfection with increasing amounts of a Rb expression construct markedly increased AR transactivation in CV-1 cells in spite of decreasing AR concentrations (Fig. 7) . In COS-7 cells, on the other hand, the decrease of AR concentrations was accompanied by a parallel decrease of AR activity. Consequently, Rb coactivates the AR in CV-1 cells but hardly at all or not in COS-7 cells. Moreover, although cotransfection of CV-1 cells with Rb increased the activity of the AR, it did not affect the degree of AR coactivation by RBaK (data not shown). Indeed, the degree of coactivation by RBaK(S) (as compared with the RBaK(AS) construct) was 3·1 after cotransfection with Rb and 3·0 without the latter. For that reason it seems unlikely that the coactivation of the AR by RBaK and by Rb are directly linked.
Androgen receptor and RBaK interaction
Discussion
From the data presented we may conclude that the LBD of the AR interacts with RBaK, a protein recently identified based on its interaction with the Rb protein (Skapek et al. 2000) , a key regulator of the cell cycle. Whereas the interaction of RBaK with Rb requires the amino-terminal region of RBaK, the interaction of RBaK with the AR occurs through the CTD of RBaK. This interaction of RBaK with the AR was confirmed by in vivo two-hybrid interaction experiments in yeast and in mammalian cells, by in vitro binding studies and by coimmunoprecipitation from nuclear extracts. Finally, cotransfection of RBaK with the AR resulted in a marked increase of AR activity, as measured by means of androgen-regulated luciferase activity, showing that RBaK functions as a coactivator under these conditions. In fact, such coactivation was observed not only for the AR, but also for the GR (results not shown), which showed weaker interaction with RBaK in the yeast two-hybrid system and in vitro. For that reason RBaK should not be considered as an AR-specific coactivator. Moreover, it should be kept in mind that our data show that RBaK interacts with the AR and coactivates its function in cotransfected cells that overexpress both proteins. This does not necessarily imply that such interaction and coactivation occur for the naturally occurring gene products. Whereas the interaction of the ARLBD with the RBaKCTD was clearly ligand-dependent in the mammalian and yeast two-hybrid experiments, this was not the case when this interaction was studied in vitro or by means of coimmunoprecipitation. The reasons for this discrepancy remain unclear, but it is conceivable that the presence of the NTD in the latter experiments may have contributed to the AR binding in the absence of ligand. It is also conceivable that the two-hybrid interactions require a tighter or sterically specific interaction, which is only realized in the presence of ligand. In any case such discrepancy is not uncommon for AR coregulators (Blanco et al. 1998 , Brady et al. 1999 , Ting et al. 2002 , which very often interact in a ligand-independent way with the AR in vitro.
The observation that cotransfection with RBaK results in coactivation rather than corepression is somewhat surprising. Indeed, structurally RBaK belongs to the subgroup of Krüppel-like zinc finger Mammalian two-hybrid interaction between Gal4 DBD-ARLBD and VP16AD-RBaKCTD. COS-7 cells (2×10 6 cells/well of a 48-well plate) were transiently transfected with 100 ng/well p(Gal4) 5 -luciferase reporter construct, 0·67 ng expression construct for the Gal4 DBD-ARLBD, and with 0·67 ng empty pSNATCHII expression vector (expressing the VP16AD), 0·67 ng expression vector for the VP16AD-RBaKCTD sense or 0·67 ng of a similar anti-sense construct as indicated. Cells were incubated for 24 h with 10 nM R1881 (black bars) or with absolute ethanol as vehicle (white bars). Thereafter, luciferase activities were measured. The luciferase activities in the absence of ligand were arbitrarily set to 1 and relative luciferase values (means±S.D.) were calculated for the conditions supplemented with ligand.
proteins, which contain an amino-terminal KRAB domain, separated from the zinc finger domain by a linker region (Bellefroid et al. 1991) . Several reports link KRAB transcriptional repression with NR functioning (Losson 1997 , de Haan et al. 2000 , but it has never been reported that a KRABcontaining protein enhances the activity of an NR. In general, the KRAB motif of these proteins results in transcriptional repressor activity through interactions with components of the basal transcription factor complex (Margolin et al. 1994 , Witzgall et al. 1994 , Lange et al. 1995 or with other coregulatory proteins, such as KAP1/TIF1 proteins (Friedman et al. 1996 , Moosmann et al. 1996 . Moreover, the KRAB domains can be linked with NR functioning via these KAP1/TIF1 proteins which interact with NRs and occur in larger complexes mediating NR activity (Underhill et al. 2000) .
As already mentioned RBaK not only interacts with the AR, but also with the Rb protein, for which AR coactivation properties have already been described in several cell lines (Lu & Danielsen 1998 , Yeh et al. 1998 . In the present report we could confirm such coactivation of the AR by Rb in CV-1 cells. Moreover, although cotransfection of RBaK resulted in a further increase of AR activity, the degree of coactivation by RBaK was similar with or without cotransfection with Rb. Finally, RBaK produced a similar degree of coactivation in COS-7 cells, wherein Rb is largely inactivated as in CV-1 cells. For that reason it seems less likely that simultaneous interactions of the AR and RBaK with Rb are required for the coactivation of the AR by RBaK in normal or tumoral cells.
The interaction of RBaK with the AR on the one hand and with the Rb protein on the other hand may contribute to the role of androgens in the regulation of the cell cycle, wherein the Rb protein functions as a crucial control mechanism. The growth suppressive effects of Rb are best characterized by its role in suppression of transcription mediated by E2F transcription activators (Dynlacht et al. 1994 , Krek et al. 1994 . In the G1 phase were transiently transfected with 100 ng/well of reporter construct (C3 ARE-luciferase), with 0·17 ng pSG5-AR and with increasing amounts (0, 0·33, 0·66 and 1·33 ng) of pSG5-Rb expression construct or an expression construct containing an unrelated cDNA fragment ( 2) of approximately the same size as the Rb insert without coregulator properties. Cells were incubated for 24 h with or without 10 nM R1881 and luciferase activities were measured. The luciferase activity in the absence of cotransfected construct was arbitrarily set to 1 and relative luciferase values were calculated for other conditions. The results shown are the means±S.D. of three independent experiments each performed in triplicate. (B) AR levels were estimated on pooled 3×10 µl aliquots of the same cell extracts.
various E2Fs are bound by Rb and hereby unable to promote cell proliferation. Upon phosphorylation of Rb, E2F is released and initiates the transcription of genes containing E2F sites in their promoter. Many of these genes are involved in cell cycle progression and DNA replication (Flemington et al. 1993 , Helin et al. 1993 , Weintraub et al. 1995 , La Thangue 1996 , Dyson 1998 , Harbour & Dean 2000 . As we could previously show in LNCaP cells (Hofman et al. 2001 ) the regulation of cell proliferation by androgens is accompanied by major changes in E2F activity. Most probably these changes are largely due to androgen-dependent changes in the phosphorylation state of Rb, mediated in turn by the activity of cyclindependent kinases and their inhibitors. However, since RBaK cotransfection has been shown to affect the E2F suppressor activity of Rb (Skapek et al. 2000) and since RBaK mRNA is present in many cells and tissues including LNCaP cells (K Hofman & W Heyns, unpublished observations), the interaction of RBaK with the AR may provide an additional level of control.
